Infectious diseases are still among the top 10 causes of death worldwide and Antimicrobial Resistance may cause an estimate of >300 million premature deaths and cost up to 100 trillion to the global economy by 2050. This so-called antibiotic resistance crisis may become a realistic scenario in the near future if no new antibiotic classes are introduced into the market to break current resistance pattern of used classes. Drug R&D is one of the most
expensive and complex activities within the pharmaceutical industry. New antibiotics are needed and this drug discovery process has to be accelerated.
To optimize and to accelerate productive R&D of novel chemical entities or new molecular entities, innovative, effective, and cost reducing methodologies are urgently needed. Novel synthetic processes using continuous, parallel flow technologies represent a new area of research with high potential for the pharmaceutical industry. For this purpose, the Institute of Chemical Research of Catalonia (ICIQ), a research Institute focused on sustainable chemistry in the field of catalysis and flow chemistry (through its technology development unit ERTFLOW) and the biotech company AiCuris Anti-infective Cures GmbH join forces to orchestrate an innovative concept of antibacterial flow chemistry. They will present this initiative to create an ITN -European Industrial Doctorate programme and the present proposal will help ICIQ, as coordinator of the proposal, to prepare the best possible application, allowing us to have training for the writing of the proposal, as well as access to reviewers and correctors. Moreover, we will be able to have meetings within the consortium to facilitate the communication and structure the project for a successful application.